Aclaris Therapeutics Inc (ACRS) Stock
Fundamentals
Recent news

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
ACRS

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
ACRS

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
ACRS

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
ACRS
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.14 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
ACRS

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
ACRS

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
ACRS

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
ACRS

3 Penny Stocks Under $5 Backed by Real Revenue Growth
3 Penny Stocks Under $5 Backed by Real Revenue Growth
ACRS

3 Penny Stocks Under $5 Backed by Real Revenue Growth
3 Penny Stocks Under $5 Backed by Real Revenue Growth
ACRS

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
ACRS

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
ACRS

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
ACRS

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
ACRS
About Aclaris Therapeutics Inc
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, CEO & Chairman | 1970 |
| Dr. Hugh M. Davis Ph.D. | President, COO & Director | 1960 |
| Mr. Kevin Balthaser | Chief Financial Officer | 1987 |
| Mr. James Loerop | Chief Business Officer | 1965 |
| Dr. Roland Kolbeck Ph.D. | Chief Scientific Officer | 1964 |
| Mr. William C. Roberts | Senior Vice President of Corporate Communications & Investor Relations | 1969 |
| Mr. Matthew Rothman J.D. | General Counsel & Corporate Secretary | — |
| Mr. Steve Tucker | Executive Vice President of Project Leadership | — |
| Dr. Jesse W. Hall M.D. | Chief Medical Officer | 1974 |
| Ms. Nina Samra M.S. | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.0 | +0.0 | -30.8 | +16.2 | ||||||||
| 2022 | -25.2 | +28.7 | +15.4 | -27.1 | -1.2 | +4.3 | +11.4 | +16.8 | -8.6 | +1.7 | -4.9 | -0.7 |
| 2023 | +12.1 | -26.6 | -33.9 | +3.0 | -9.7 | +19.2 | -5.7 | -23.8 | -13.3 | -23.3 | -82.9 | +16.7 |
| 2024 | +10.5 | -0.8 | +0.0 | -4.0 | -18.3 | +5.8 | +16.5 | -10.6 | +0.0 | +53.4 | +94.7 | -37.4 |
| 2025 | +0.0 | -17.1 | -21.9 | -6.8 | +5.8 | -1.4 | +8.5 | +26.1 | -4.5 | +34.8 | +10.5 | +15.3 |
| 2026 | +21.9 | -20.5 | +23.0 | +4.8 | +3.2 | +21.9 | -2.6 | +9.4 | -14.5 |



